FirsthandHealth
medRxiv PreprintsInternational17 November 2026

Whole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Accurate genetic characterization is central to modern acute myeloid leukemia (AML) diagnostics, yet current standard-of-care (SoC) testing relies on multiple complementary assays. We compared paired tumor-normal whole-genome sequencing (WGS) with SoC diagnostics in a population-based cohort of 109 adult AML patients, assessing variant detection, disease classification according to ICC 2022 and WHO 2022, and risk stratification according to ELN 2022. WGS showed high concordance with SoC across variant classes. When considering all reported SoC variants together with high-confidence WGS variant
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.